Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

As the next round of Medicare drug pricing negotiations get underway, experts predict President Trump may seek to weaken the program.

Despite online claims, President Donald Trump’s executive orders did not include removing Medicare’s $35 monthly out-of-pocket price cap, which is set by law.

Democrat U.S. Senators Urge President Trump to Reject Big Pharma’s Push to End Medicare Price Negotiations, Protect Medicare Enrollees ...

A letter from several Democratic Senators urged Trump to use his deal-making skills to “flat out reject any request to end ...

A group of lawmakers are urging President Donald Trump to reject pharmaceutical companies’ efforts to pause the Biden ...

Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity ...